Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information

Paola Minetto, Fabio Guolo, Marino Clavio, Annalisa Kunkl, Nicoletta Colombo, Enrico Carminati, Giuseppina Fugazza, Simona Matarese, Daniela Guardo, Filippo Ballerini, Carmen Di Grazia, Anna M. Raiola, Antonia Cagnetta, Michele Cea, Maurizio Miglino, Roberto M. Lemoli, Marco Gobbi

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
JournalBritish Journal of Haematology
DOIs
Publication statusAccepted/In press - Jan 1 2018

Keywords

  • Acute myeloid leukaemia
  • Flow cytometry
  • Fludarabine
  • Fludarabine, cytarabine, idarubicin
  • Minimal residual disease

ASJC Scopus subject areas

  • Hematology

Cite this